2013, № 4 (153)

1. Tankovskiy V.E. Retinal vein occlusions. М.: Voenizdat. — 2000. 262 pp.

2. Tarasova L.N., Kiseleva T.N., Fokin A.A. Eye ischemic syndrome. М.: Medicina. — 2003. — 172 pp.

3. Kiseleva T.N., Koshevaya O.P., Budzinskaya M.V., Schegoleva I.V., Kravchuk E.A. The value of doppler carting in diagnostics of occlusive disorders of retinal veins // Vestn. ophthalmologii. — 2006. — №5. — P. 4-7.

4. Central Vein Occlusion Study Group: A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: The Central Vein Occlusion Study Group N report // Ophthalmology. — 1995. — Vol. 102. — P. 1434-1444.

5. Starkov G.L. Epidemiology of retinal pathology. // Ophthalmologicheskiy zhurnal. — 1987. — №2. — P. 69-72;

6. Jalkh A.E., Trempe C.L. Macular edema in branch retinal vein occlusion: types and treatment // Ophthalmic Surg. — 1989. — Vol. 20 — №1. — P. 26-32.

7. Katsnelson L.A., Forofonova T.I., Bunin A.Ya. Vascular diseases of the eyes. М.: Medicina. — 1990. — 270 pp.

8. Davidova N.G., Muha A.I., Annamedov G.A. The results of using tiklid for the treatment of patients with postocclusive retinopathy // Vestn. Ophthalmologii. — 1992. — №2. — P. 22-24.

9. Bandello F., D'Angelo S.V., Parlovecchia M. et al. Hypercoagulability and high lipoprotein(a) levels in patients with central retinal vein occlusion // Thromb. Haemost. — 1994. — Vol. 72. — №7. — P. 9-43.

10. Abe S., Shiono T. Retinochoroidal circulatory disturbances and blood component abnormalities // Nippon Gakkai Zasshi. — 1995. — Vol. 99. — №3. — P. 255-261.

11. Shima D., Adamis A.P., Ferrara N. et al. Hypoxic induction of endothelial cell growth factor in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen // Mol. Med. — 1995. — Vol. 1. — №2. — P. 182-193.

12. Aiello L.P., Avery R.L., Arrigg P.G. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders // N Engl J Med. — 1994;331:1480-1487;

13. Hoch R.V., Soriano P. Roles of PDGF in animal development // Development. — 2003. — №130. — Р. 4769–4784;

14. Adamis A.P., Miller J., Bernal M. et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy // Am J Ophthalmol. — 1994. — Vol. 118. — №4. — P. 445-450.

15. Yogi A., O'Connor S.E., Callera G.E. et al. Receptor and nonreceptor tyrosine kinases in vascular biology of hypertension // Curr Opin Nephrol Hypertens. — 2010. — №19(2). — Р. 169–176.

16. Mohle R., Green D., Moore M.A., Nachman R.L., Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. // Proc Natl Acad Sci USA. — 1997. — 94: P. 663-668.

17. Solanilla A., Villeneuve J., Auguste P., Hugues M., Alioum A., Lepreux S., Ducroix J., Duhaut P., Conri C., Viallard J., Nurden A.T., Constans J., Ripoche J. The transports of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis // Rheumatology. — 2009. — 48: P. 1036-1044.

18. Banks R.E., Forbes M.A., Kinsey S.E. et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology // Br J Cancer. — 1998. — 77: P. 956-964.

19. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. // Nat Rev Drug Discov. — 2004. — 3: P. 391-400.

20. Collet L., Larson T.A., Bakri S.J. Bevacizumab for Ophthalmic Disease // US Ophthalmic Review. — 2007. — P. 20-24.

21. Nalluri S.R., Chu D., Kerszetes R., Zhu X., Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients // JAMA. — 2008. — 300(19): P. 2277-2285.

22. Scappaticci F.A., Skillings J.R., Holden S.N., Gerber H.P., Miller K., Kabbinavar F. et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab // J Natl Cancer Inst. — 2007. — 99(16): P. 1232-1239.

23. Schutz F.A.B., Je Y., Azzi G.R., Nguyen P.L., Choueiri T.K. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes // Ann Oncol. Nov 29. 2010 [Epub ahead of print].

24. Selheim F., Holmsen H., Vassbotn F.S. Identification of functional VEGF receptors on human platelets // FEBS Lett. — 2002. — 512(1-3): P. 107-110.

25. Meyer T., Robles-Carillo L., Robson T., Langer F., Desai H., Davila M. et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice // J Thromb Haemost. — 2009. — 7(1): P. 171-181.

26. Salgado R., Benoy I., Bogers J., Weytjens R., Vermeulen P., Dirix L. et al. Platelets and vascular endothelial growth factor (VEGF): A morphological and functional study // Angoigenesis. — 2001. — 4(1): P. 37-43.

27. Katoh O., Tauchi H., Kawaishi K., Kimura A., Satow Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptic cell death caused by ionizing radiation // Cancer Res. — 1995. — 55(23): P. 5687-5692.

28. Fehr M., Catschegn S., Reinhart W.H., Madon J., Asmis L., Cathomas R., von Moos R. The influence of bevacizumab on platelet function // Swiss Med Wkly. — 2011. — 141: w13243

29. Born G., Hume M. Effects of the numbers and sizes of platelet aggregates on the optical density of plasma // Nature. — 1967. — 215(5105): Р. 1027-1029.

30. Gabbasov Z., Popov E., Gavrilov I., Pozin E. Platelet aggregation: the use of optical density fluctuations to study microaggregate formation in platelet suspension // Thromb Res. — 1989. — 54(3): Р. 215-223.

About this article